Key facts
- Hong Kong seeks to boost its clinical trial capabilities.
- The government plans to attract top-notch innovative enterprises.
- Measures include extending R&D networks and expediting clinical trials.
- Drug registration approval acceleration is a key objective.
- Special measures allow use of HK-registered drugs in the GBA.
Hong Kong is detailing its vision for the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) as part of its first five-year plan. The government is committed to enhancing the city's clinical trial capabilities and facilitating the translation of biomedical research into clinical applications. This includes extending the research and development network and expediting clinical trials. The administration also aims to accelerate the registration of new drugs in Hong Kong, mainland China, and overseas, while attracting innovative enterprises to establish operations in the region. Special measures are in place to allow the use of Hong Kong-registered drugs and medical devices in public hospitals within the GBA. The Greater Bay Area has a population of over 86 million.